Clinical Cardiac Magnetic Resonance Spectroscopy

Progress in Cardiovascular Diseases

Volumn 54, Issue 3, 2011, Pages 320-327

  Holloway, Cameron J ^a   Suttie, Joseph ^a   Dass, Sairia ^a   Neubauer, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiac energy metabolism; Cardiac magnetic resonance spectroscopy; High energy phosphate metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE; CREATININE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DIABETES MELLITUS; DIETARY INTAKE; ENERGY METABOLISM; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HUMAN; HYPERPOLARIZATION; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PHOSPHATE METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; SODIUM NUCLEAR MAGNETIC RESONANCE; VALVULAR HEART DISEASE;

ENERGY METABOLISM; HEART DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 80054783136     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.08.002     Document Type: Article

References (56)

1. Kankaanpaa M., Lehto H.R., Parkka J.P., et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006, 91:4689-4695.
2. Ingwall J.S., Kramer M.F., Fifer M.A., et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 1985, 313:1050-1054.
3. Cross H.R., Radda G.K., Clarke K. The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Magn Reson Med 1995, 34:673-685.
4. Ten Hove M., Van Echteld C.J.A. Limited effects of post-ischemic NHE blockade on [Na+]i and pHi in rat hearts explain its lack of cardioprotection. Cardiovasc Res 2004, 61:522-529.
5. Kupriyanov V.V., Gruwel M.L. Rubidium-87 magnetic resonance spectroscopy and imaging for analysis of mammalian K+ transport. NMR Biomed 2005, 18:111-124.
6. Schroeder M.A., Atherton H.J., Ball D.R., et al. Real-time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J 2009, 23:2529-2538.
7. Tyler D.J., Emmanuel Y., Cochlin L.E., et al. Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T. NMR Biomed 2009, 22:405-413.
8. Naressi A., Couturier C., Castang I., et al. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001, 31:269-286.
9. Szczepaniak L.S., Dobbins R.L., Metzger G.J., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49:417-423.
10. Ng A.C.T., Delgado V., Bertini M., et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 2010, 122:2538-2544.
11. Horn M., Weidensteiner C., Scheffer H., et al. Detection of myocardial viability based on measurement of sodium content: a (23)Na-NMR study. Magn Reson Med 2001, 45:756-764.
12. Sandstede J.J., Pabst T., Beer M., et al. Assessment of myocardial infarction in humans with (23)Na MR imaging: comparison with cine MR imaging and delayed contrast enhancement. Radiology 2001, 221:222-228.
13. Sandstede J.J., Hillenbrand H., Beer M., et al. Time course of 23Na signal intensity after myocardial infarction in humans. Magn Reson Med 2004, 52:545-551.
14. Merritt M.E., Harrison C., Storey C., et al. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci U S A 2007, 104:19773-19777.
15. Beer M., Viehrig M., Seyfarth T., et al. Cardiac energy metabolism in heart valve diseases with 31P MR spectroscopy. Radiologe 2000, 40:162-167.
16. Sardanelli F., Zandrino F., Molinari G., et al. Magnetic resonance spectroscopy of ischemic heart disease. Rays 1999, 24:149-164.
17. Neubauer S., Krahe T., Schindler R., et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992, 86:1810-1818.
18. Bottomley P.A., Wu K.C., Gerstenblith G., et al. Reduced myocardial creatine kinase flux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study. Circulation 2009, 119:1918-1924.
19. Weiss R.G., Bottomley P.A., Hardy C.J., et al. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 1990, 323:1593-1600.
20. Buchthal S.D., den Hollander J.A., Merz C.N., et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000, 342:829-835.
21. Johnson B.D., Shaw L.J., Buchthal S.D., et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:2993-2999.
22. Bottomley P.A., Weiss R.G. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 1998, 351:714-718.
23. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
24. Ingwall J.S., Atkinson D.E., Clarke K., et al. Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium. Eur Heart J 1990, 11(Suppl B):108-115.
25. Neubauer S., Horn M., Pabst T., et al. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995, 16(Suppl O):115-118.
26. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190-2196.
27. Crilley J.G., Boehm E.A., Rajagopalan B., et al. Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol 2000, 36:1953-1958.
28. Beer M., Seyfarth T., Sandstede J., et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002, 40:1267-1274.
29. Weiss R.G., Gerstenblith G., Bottomley P.A. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A 2005, 102:808-813.
30. Beer M., Wagner D., Myers J., et al. Effects of exercise training on myocardial energy metabolism and ventricular function assessed by quantitative phosphorus-31 magnetic resonance spectroscopy and magnetic resonance imaging in dilated cardiomyopathy. J Am Coll Cardiol 2008, 51:1883-1891.
31. Nakae I., Mitsunami K., Yoshino T., et al. Clinical features of myocardial triglyceride in different types of cardiomyopathy assessed by proton magnetic resonance spectroscopy: comparison with myocardial creatine. J Card Fail 2010, 16:812-822.
32. Tian R. Energetic basis of diastolic dysfunction. MAGMA 1998, 6:129-131.
33. Scheuermann-Freestone M., Madsen P.L., Manners D., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040-3046.
34. Phan T.T., Abozguia K., Nallur Shivu G., et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009, 54:402-409.
35. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006, 27:942-948.
36. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003, 41:1776-1782.
37. Jung W.I., Sieverding L., Breuer J., et al. Detection of phosphomonoester signals in proton-decoupled 31P NMR spectra of the myocardium of patients with myocardial hypertrophy. J Magn Reson 1998, 133:232-235.
38. Jung W.I., Hoess T., Bunse M., et al. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation 2000, 101:E121.
39. Shivu G.N., Abozguia K., Phan T.T., et al. (31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: experiences at 3T. Eur J Radiol 2008.
40. Abozguia K., Elliott P., McKenna W., et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010, 122:1562-1569.
41. Conway M.A., Allis J., Ouwerkerk R., et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991, 338:973-976.
42. Neubauer S., Horn M., Pabst T., et al. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy. J Investig Med 1997, 45:453-462.
43. Beyerbacht H.P., Vliegen H.W., Lamb H.J., et al. Phosphorus magnetic resonance spectroscopy of the human heart: current status and clinical implications. Eur Heart J 1996, 17:1158-1166.
44. Metzler B., Schocke M.F., Steinboeck P., et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson 2002, 4:493-502.
45. McGavock J.M., Lingvay I., Zib I., et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007, 116:1170-1175.
46. Rijzewijk L.J., van der Meer R.W., Smit J.W., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799.
47. Hammer S., Snel M., Lamb H.J., et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008, 52:1006-1012.
48. van der Meer R., Hammer S., Lamb H., et al. Effects of short-term high-fat, high energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab 2008, 93:2702-2708.
49. Holloway C.J.., Cochlin L.E., Emmanuel Y., et al. A high-fat diet impairs cardiac high-energy phosphate metabolism and cognitive function in healthy human subjects. Am J Clin Nutr 2011, 93:748-755.
50. Van Dobbenburgh J.O., Lahpor J.R., Woolley S.R., et al. Functional recovery after human heart transplantation is related to the metabolic condition of the hypothermic donor heart. Circulation 1996, 94:2831-2836.
51. Fraser C.D., Chacko V.P., Jacobus W.E., et al. Early phosphorus 31 nuclear magnetic resonance bioenergetic changes potentially predict rejection in heterotopic cardiac allografts. J Heart Transplant 1990, 9:197-204.
52. Bottomley P.A., Weiss R.G., Hardy C.J., et al. Myocardial high-energy phosphate metabolism and allograft rejection in patients with heart transplants. Radiology 1991, 181:67-75.
53. Evanochko W.T., Buchthal S.D., den Hollander J.A., et al. Cardiac transplant patients response to the (31)P MRS stress test. J Heart Lung Transplant 2002, 21:522-529.
54. Tyler D.J., Hudsmith L.E., Clarke K., et al. A comparison of cardiac (31)P MRS at 1.5 and 3 T. NMR Biomed 2008.
55. Speck O., Scheffler K., Hennig J. Fast 31P chemical shift imaging using SSFP methods. Magn Reson Med 2002, 48:633-639.
56. Lee R.F., Giaquinto R., Constantinides C., et al. A broadband phased-array system for direct phosphorus and sodium metabolic MRI on a clinical scanner. Magn Reson Med 2000, 43:269-277.